Table 3.
Patients’ characteristics according to CXCR4 positive tumor expression in recurrent cancer biopsiesa
| CXCR4 high | CXCR4 low | p-value | |
|---|---|---|---|
| n = 22 (100%) | n = 21 (100%) | ||
| Age (median, range) | 58.5 (34-77) | 57 (41-76) | 0.458 |
| FIGO stage | |||
| II | 1 (4.5) | 0 (0) | |
| IIIA | 1 (4.5) | 0 (0) | |
| IIIB | 2 (9.1) | 3 (14.3) | 0.715 |
| IIIC | 13 (59.1) | 15 (71.4) | |
| IV | 5 (22.7) | 3 (14.3) | |
| Residual disease | |||
| None | 10 (45.5) | 5 (23.8) | |
| <2cm | 8 (36.4) | 7 (33.3) | 0.266 |
| >2cm | 4 (18.2) | 8 (38.1) | |
| Numbers of chemotherapy cycles | |||
| <6 | 7 (31.8) | 0 (0) | 0.006 |
| 6 or more | 15 (68.2) | 20 (95.2) | |
| CSb | 18 (81.8) | 12 (57.1) | 0.078 |
| CRb | 4 (18.2) | 9 (42.9) | |
| 6-month recurrent free survival % (95%CI)c | 0.68 (0.45-0.83) | 0.48 (0.26-0.67) | 0.018 |
| 3-year overall survival % (95%CI)c | 0.50 (0.23-0.72) | 0.50 (0.25-0.71) | 0.207 |
aCut-off = 84 cells/punch, n = 43. Percentages may not add to 100% due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random. Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kaplan-Meier method. FIGO stage, residual disease, numbers of chemotherapy cycles and chemoresistance were analyzed using the Chi-Square or the Fisher’s Exact test.
bCS chemosensitive, CR chemoresistant
cRFS recurrence-free survival, OS overall survival